Your browser doesn't support javascript.
loading
Efficacy and safety of tadalafil 5 mg once daily for lower urinary tract symptoms suggestive of benign prostatic hyperplasia: subgroup analyses of pooled data from 4 multinational, randomized, placebo-controlled clinical studies.
Porst, Hartmut; Oelke, Matthias; Goldfischer, Evan R; Cox, David; Watts, Steven; Dey, Debashish; Viktrup, Lars.
Afiliação
  • Porst H; Department of Urology, Hannover Medical School, Hannover, Germany. Porst20354@aol.com
Urology ; 82(3): 667-73, 2013 Sep.
Article em En | MEDLINE | ID: mdl-23876588
ABSTRACT

OBJECTIVE:

To assess the efficacy and safety of tadalafil, a phosphodiesterase 5 (PDE5) inhibitor efficacious for erectile dysfunction and lower urinary tract symptoms suggestive of benign prostatic hyperplasia (LUTS/BPH), in population subgroups, using pooled data from 4 international, randomized, placebo-controlled studies in men with LUTS/BPH.

METHODS:

The safety database included 1500 men randomized to tadalafil 5 mg once daily or placebo for 12 weeks. Changes in total International Prostate Symptom Score (IPSS), IPSS-quality of life index, and BPH impact index were examined overall, and changes in IPSS or adverse events (AEs) were examined across subgroups of interest. Treatment-group differences were assessed using analysis of covariance.

RESULTS:

Results of pooled data confirmed that tadalafil (N = 752) resulted in significant improvements from baseline vs placebo (N = 746) in IPSS (mean difference -2.3; P <.001), and also in BPH impact index and IPSS-quality of life index (both P <.001). Subgroup analyses demonstrated that IPSS improvements were significant regardless of baseline LUTS severity (IPSS <20/≥20), age (≤65/>65 years), recent previous use of α-blockers or PDE5 inhibitors, total testosterone level (<300/≥300 ng/dL), or prostate-specific antigen predicted prostate volume (<40/≥40 mL). [corrected] Rates of treatment emergent AEs were comparable between subgroups of baseline age (≤65/>65 years), previous PDE5 inhibitor use, and the presence or absence of pre-existing diabetes, hypertension, or cardiovascular disease (including hypertension), but somewhat higher for recent previous α-blocker use.

CONCLUSION:

In these pooled data analyses, tadalafil 5 mg improved LUTS/BPH across subgroups of age, LUTS severity, testosterone levels, and prostate volume. Rates of AEs were similar across the subgroups assessed.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Próstata / Carbolinas / Inibidores da Fosfodiesterase 5 / Sintomas do Trato Urinário Inferior Tipo de estudo: Clinical_trials / Diagnostic_studies / Prognostic_studies Limite: Aged / Humans / Male / Middle aged Idioma: En Ano de publicação: 2013 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Próstata / Carbolinas / Inibidores da Fosfodiesterase 5 / Sintomas do Trato Urinário Inferior Tipo de estudo: Clinical_trials / Diagnostic_studies / Prognostic_studies Limite: Aged / Humans / Male / Middle aged Idioma: En Ano de publicação: 2013 Tipo de documento: Article